XERIS BIOPHARMA HOLDINGS, INC. Basic Shares Outstanding (Weighted Average)
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Basic Shares Outstanding (Weighted Average) of 172.82 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 172.82M shares, a 8.38% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 170.52M shares, a 11.86% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 166.02M shares, a 11.27% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 163.65M shares, a 9.84% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 160.43M shares, a 9.30% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 146.77M shares, a 6.61% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 137.67M shares, a 1.51% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 135.63M shares, a 71.62% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 172.82M shares 10-Q · filed 2026-08-06 | 171.68M shares 10-Q · filed 2026-08-06 | 169.79M shares derived: average of 3 quarters · filed 2026-08-06 | 168.25M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 170.52M shares 10-Q · filed 2026-05-07 | 168.27M shares derived: average of 2 quarters · filed 2026-05-07 | 166.73M shares derived: average of 3 quarters · filed 2026-05-07 | 164.91M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 166.02M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 164.84M shares derived: average of 2 quarters · filed 2026-03-02 | 163.04M shares derived: average of 3 quarters · filed 2026-08-06 | 160.43M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 163.65M shares 10-Q · filed 2025-11-06 | 161.55M shares derived: average of 2 quarters · filed 2026-08-06 | 158.56M shares 10-Q · filed 2025-11-06 | 156.19M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 159.46M shares 10-Q · filed 2026-08-06 | 155.97M shares 10-Q · filed 2026-08-06 | 153.70M shares derived: average of 3 quarters · filed 2026-08-06 | 152.53M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 152.45M shares 10-Q · filed 2026-05-07 | 150.83M shares derived: average of 2 quarters · filed 2026-05-07 | 150.21M shares derived: average of 3 quarters · filed 2026-05-07 | 149.75M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 149.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 149.10M shares derived: average of 2 quarters · filed 2026-03-02 | 148.85M shares derived: average of 3 quarters · filed 2026-03-02 | 146.77M shares 10-K · filed 2026-03-02 |
| 2024-09-30 | 148.99M shares 10-Q · filed 2025-11-06 | 148.67M shares derived: average of 2 quarters · filed 2025-11-06 | 145.96M shares 10-Q · filed 2025-11-06 | 144.00M shares derived: average of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | 148.35M shares 10-Q · filed 2025-08-07 | 144.37M shares 10-Q · filed 2025-08-07 | 142.33M shares derived: average of 3 quarters · filed 2026-03-02 | 141.26M shares derived: average of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | 140.51M shares 10-Q · filed 2025-05-08 | 139.32M shares derived: average of 2 quarters · filed 2026-03-02 | 138.90M shares derived: average of 3 quarters · filed 2026-03-02 | 138.51M shares derived: average of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | 138.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 138.09M shares derived: average of 2 quarters · filed 2026-03-02 | 137.84M shares derived: average of 3 quarters · filed 2026-03-02 | 137.67M shares 10-K · filed 2026-03-02 |
| 2023-09-30 | 138.06M shares 10-Q · filed 2024-11-08 | 137.70M shares derived: average of 2 quarters · filed 2024-11-08 | 137.52M shares 10-Q · filed 2024-11-08 | 137.13M shares derived: average of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | 137.34M shares 10-Q · filed 2024-08-08 | 137.25M shares 10-Q · filed 2024-08-08 | 136.82M shares derived: average of 3 quarters · filed 2025-03-06 | 136.61M shares derived: average of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | 137.14M shares 10-Q · filed 2024-05-09 | 136.57M shares derived: average of 2 quarters · filed 2025-03-06 | 136.36M shares derived: average of 3 quarters · filed 2025-03-06 | 136.15M shares derived: average of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | 135.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 135.97M shares derived: average of 2 quarters · filed 2025-03-06 | 135.82M shares derived: average of 3 quarters · filed 2025-03-06 | 135.63M shares 10-K · filed 2025-03-06 |
| 2022-09-30 | 135.95M shares 10-Q · filed 2023-11-09 | 135.74M shares derived: average of 2 quarters · filed 2023-11-09 | 135.51M shares 10-Q · filed 2023-11-09 | 132.11M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 135.53M shares 10-Q · filed 2023-08-08 | 135.28M shares 10-Q · filed 2023-08-08 | 130.83M shares derived: average of 3 quarters · filed 2023-08-08 | 114.75M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 135.03M shares 10-Q · filed 2023-05-09 | 128.49M shares derived: average of 2 quarters · filed 2023-05-09 | 107.82M shares derived: average of 3 quarters · filed 2023-05-09 | 97.46M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 121.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | 94.22M shares derived: average of 2 quarters · filed 2023-03-08 | 84.94M shares derived: average of 3 quarters · filed 2023-03-08 | 79.03M shares 10-K · filed 2023-03-08 |
| 2021-09-30 | 66.50M shares 10-Q · filed 2022-11-09 | 66.43M shares derived: average of 2 quarters · filed 2022-11-09 | 64.72M shares 10-Q · filed 2022-11-09 | |
| 2021-06-30 | 66.37M shares 10-Q · filed 2022-08-10 | 63.82M shares 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 61.25M shares 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |